Loading...
•
Jun 30
iBio Q4 2025 Earnings Report
iBio reported a narrower loss and modest revenue growth in the fourth quarter of fiscal 2025.
Key Takeaways
iBio's Q4 2025 performance showed progress, with revenue reaching $200,000 and net loss narrowing to $4.46 million. The company continued advancing its preclinical pipeline targeting obesity and cardiometabolic diseases.
Generated $200,000 in revenue during Q4, up from zero in prior quarters.
Reported net loss of $4.46 million, an improvement from earlier quarters.
EPS for the quarter came in at -0.31 based on full-year and prior quarter data.
Continued development of IBIO-610 showing promising preclinical results for fat-selective weight loss.
iBio
iBio
Forward Guidance
iBio enters FY26 positioned to advance its clinical drug candidates and expand its preclinical portfolio.
Positive Outlook
- Secured $6.2M through warrant inducement transaction.
- Raised up to $100M in potential gross proceeds via public offering.
- Advanced multiple obesity and cardiometabolic disease programs.
- Strengthened leadership team with industry veterans.
- Continued development of IBIO-610 and IBIO-600 with promising preclinical data.
Challenges Ahead
- Operating losses remain significant.
- Minimal revenue generation from core programs.
- No product candidates have reached clinical trials yet.
- High dependency on external financing.
- Continued R&D and G&A costs may pressure future cash flows.